Lyell Immunopharma, Inc. Depreciation
Lyell Immunopharma, Inc. (LYEL) reported Depreciation of $10.40 million for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-12.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-03-12
- Lyell Immunopharma, Inc. depreciation for fiscal 2025 was $10.40M, a 46.39% decline from fiscal 2024.
- Lyell Immunopharma, Inc. depreciation for fiscal 2024 was $19.40M, a 3.96% decline from fiscal 2023.
- Lyell Immunopharma, Inc. depreciation for fiscal 2023 was $20.20M, a 12.22% increase from fiscal 2022.
- Lyell Immunopharma, Inc. depreciation for fiscal 2022 was $18.00M, a 33.33% increase from fiscal 2021.
| Period end | Depreciation 12 month |
|---|---|
| 2025-12-31 | $10.40M 10-K · filed 2026-03-12 |
| 2024-12-31 | $19.40M 10-K · filed 2026-03-12 |
| 2023-12-31 | $20.20M 10-K · filed 2026-03-12 |
| 2022-12-31 | $18.00M 10-K · filed 2025-03-11 |
| 2021-12-31 | $13.50M 10-K · filed 2024-02-28 |
| 2020-12-31 | $4.20M 10-K · filed 2023-02-28 |
| 2019-12-31 | $1.30M 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |